Valeant Pharmaceuticals Intl Inc.: Jim Chanos and the Original Short Thesis

Jim Chanos was short Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) before the company ran into problems.

| More on:
The Motley Fool

Jim Chanos has long been one of Wall Street’s best skeptics; he’s best known for betting against Enron before the company’s collapse. And Mr. Chanos was also betting against Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) back when the company was widely admired. Oddly enough, many of Valeant’s current problems were unforeseen by Mr. Chanos (or anyone else for that matter).

So why exactly did Mr. Chanos bet against Valeant? And what does it mean for the stock today?

A “roll-up”

Interestingly, Mr. Chanos did not bet against Enron because he uncovered a fraud. Rather, he said he didn’t think Enron was a good business. Likewise, Mr. Chanos did not bet against Valeant because he unearthed fraudulent activity at Philidor. In fact, he was short before Valeant was even consolidating Philidor.

Mr. Chanos was shorting Valeant because he saw the company as a roll-up, a term used to describe companies that rely on acquisitions to grow. He explained his reasoning in an interview with CNBC back in May 2014:

We’re short because it’s a roll-up and roll-ups present a unique set of problems. Roll-ups are generally accounting-driven, and we certainly think that’s the case in Valeant. We think that Valeant is playing some very aggressive accounting games when they buy companies, write down the assets.

Mr. Chanos also claimed during the interview that Valeant needed acquisitions to cover up poor fundamentals.

For quite a while, he had to eat his words. Valeant shares were trading for about US$123 during that interview, and over 15 months, they surged by more than 100%. But he stuck to his guns and has been rewarded handsomely for it.

What does this mean for Valeant today?

Valeant has a lot of pressing concerns. The company has not filed audited financial statements for 2015. There is a mountain of debt. The Philidor scandal is still ongoing. Regulators and lawmakers are investigating the company.

And because of Valeant’s weakened state, the company will not be doing any major acquisitions. There may even be some divestitures in the works. This brings me back to Mr. Chanos’s thesis. If he was right, then the true Valeant–one with very weak fundamentals–will be on full display now that acquisitions cannot be used to cover up the mess.

Even if Mr. Chanos is half-right, then Valeant shareholders are due for a lot more pain. I am glad not to be one of those people.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Energy Stocks

Why Shares of Cameco Are Powering Higher

Cameco (TSX:CCO) shares have surged more than 400% in the last five years alone, with more growth on the way.

Read more »

A bull outlined against a field
Stocks for Beginners

Bull Market Buys: 2 TSX Stocks to Own for the Long Run

Are you looking for stocks that could see a bull run for decades ahead? Here are two top TSX stocks…

Read more »

financial freedom sign
Dividend Stocks

Million-Dollar TFSA: 1 Way to Achieve to 7-Figure Wealth

Achieving seven-figure TFSA wealth is doable with two large-cap, high-yield dividend stocks.

Read more »

analyze data
Dividend Stocks

How Much Will Manulife Financial Pay in Dividends This Year?

Manulife stock's dividend should be safe and the stock appears to be fairly valued.

Read more »

food restaurants
Dividend Stocks

Better Stock to Buy Now: Tim Hortons or Starbucks?

Starbucks and Restaurant Brands International are two blue-chip dividend stocks that trade at a discount to consensus price targets.

Read more »

Diggers and trucks in a coal mine
Metals and Mining Stocks

1 Canadian Mining Stock Worth a Long-Term Investment

Cameco (TSX:CCO) stock could be a great long-term investment for Canadian growth seekers.

Read more »

Pot stocks are a riskier investment

Could Investing $10,000 in Aurora Cannabis Stock Make You a Millionaire?

Let's dive into whether Aurora Cannabis (TSX:ACB) could be a potential millionaire-maker stock, or a dud, over the long term.

Read more »

stock analysis
Energy Stocks

Is Enbridge Stock a Good Buy in May 2024?

Boasting high-yielding dividends and a stable underlying business, Enbridge (TSX:ENB) might be a great buy for your self-directed investment portfolio…

Read more »